anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Thin periodontal phenotype will be treated with i-PRF procedure. A total of 4 sessions will be done with an interval of 10 days each. And all the parameters will be measured.
Hemostasis in peripheral vascular surgery is made more difficult by the need for direct arterial and arterial graft suturing as well as by systemic anticoagulation to prevent thrombosis during periods of vascular occlusion. Polytetrafluorethylene (PTFE) is one of the most frequently used graft materials for vascular replacement or bypass in the case when no autologous venae are available (1). However, the insufficient elasticity of PTFE and its porosity promote the development of suture hole bleeding (2,3) which can cause considerable loss of blood and prolongation of operations (2).

This study is designed to demonstrate the superiority of Lyostypt® to oxidized cellulose (Surgicel®) for hemostasis of suture hole bleeding in arterial bypass anastomoses after vascular reconstruction. Lyostypt® is an absorbable, wet stable collagen compress made of collagen fibrils of bovine origin. Collagen leads to thrombocyte adhesion and to activation of coagulation factor XII. Therefore collagen is very effective in hemostasis. Collagen is cell-friendly whereas other hemostats significantly disturb cell growth. Advantages of collagen fleece are fast induction of hemostasis, low tissue reaction and fast absorption (15). Furthermore, collagen was shown to be the best overall hemostatic agent in microvascular surgery. Authors concluded that collagen fleece establish faster hemostasis than oxidized cellulose and that it was resorbed faster than oxidized cellulose (15).
Participants (50 children and 50 young adults for part A, and 50 other children and 50 other young adults) will be exposed to virtual experience having different level of realism. In one condition the realism will be high (very close to the real word) and in the second condition the realism will be low (comparable to cartoon). The stimuli of interest included in virtual experience will be of three emotional categories : negative, positive and neutral.
Improved cyclamenaldehyde derivatives, and fragrances and flavorings including the derivatives, are disclosed. In particular, the derivatives maintain the fragrance characteristics of cyclamenaldehyde, while enhancing the odorant intensity. In addition, when present in a fragrance they heighten the effect of the remainder of the formulation. Further, they heighten the perceived intensity of other olfactory stimuli, e.g. food and ambient smells. Also disclosed are methods of making the derivatives, and articles of manufacture including the derivatives. The derivatives are prepared by replacing the phenyl moiety in cyclamenaldehyde with a thiophene moiety, which can be unsubstituted, or substituted with one or two lower alkyl, preferably isopropyl groups. The aldehyde group in cyclamenaldehyde can also be replaced with an acetal, methyl ether, nitrile or ester functionality. The acetal groups can provide the compounds with a long lasting flavor or fragrance, where the acetals slowly hydrolyze to provide the aldehyde group in cyclamenaldehyde. Examples of suitable articles of manufacture include perfumes, colognes, candles, air fresheners, and disinfectant compositions.
Artesunate 200 mg PO once a day x 2 weeks. Curcumin 2 gm PO once a day x 13 weeks.
Blood and saliva specimens will be taken for ctDNA analysis at baseline, weekly during treatment and at 2 weeks after treatment. During follow up both blood and saliva will be obtained in combination with a CT/MRI scan on the same day at 3 months, 6 months, 1 year and 2 years after treatment.
Arm 1 includes inflammatory-disease-free HCs. Arm 1 was designed to evaluate image/re-image consistency (repeatability and stability) of joint-specific and global TUVs across a variety of image acquisition intervals and to collect normative HC data.
Apparatus for making miniature capsules having a capsule-forming orifice defined by the open ends of two coaxial conduits. The inner conduit defines a central opening in the orifice and the outer conduit defines an annulus circumferentially of the central opening. Filter-content material for the individual capsules is extruded as a stream through the central opening and a settable coating liquid material is extruded as a thin film sleeve circumferentially of the filler-content material stream. The film sleeve and the stream of filler-content material pass through a cooling liquid which is flowed through a fixed nozzle downstream of the extruding orifice. The nozzle has an inlet section with converging inner surfaces and a uniform diameter downstream of the inlet section. The cooling fluid, the film sleeve and filler-content stream therein all pass through the nozzle. A driven annular vibrator is disposed within the nozzle and develops vibrations in the cooling fluid parallel to the direction of the path of travel of the flow to form discrete droplets of the filler-content material enclosed in a film of the settable material. The droplets are recovered as miniature capsules.
The invention discloses a dinitrate amine solid dispersion and a preparation method thereof. According to the invention, the particle size of the material is reduced to the nano-scale by mechanical ball milling assistance, so that the material enters into a gap between auxiliary material solubilizers with solubilization to form inclusion compound, and the solubility of the inclusion compound is increased. The specific process comprises the following steps: and (3) placing the dinitolmide and the auxiliary materials into a ball milling tank, and adding ball milling beads with a certain proportion for grinding. And the formulation proportion, grinding time, grinding speed, filling rate and the like of the polishing composition are examined. Obtaining a set of material formula and ball milling process with better quality. The invention has the characteristics of simple preparation method, no need of organic solvent, good uniformity of drug content, increased solubility in water of the obtained solid dispersion, good anticoccidial effect and the like, and has potential prospects in the fields of veterinary drug production and application.
BACKGROUND: Multiple sclerosis (MS) represents a multifaceted autoimmune ailment, prompting the development and widespread utilization of numerous therapeutic interventions. However, extant medications for MS have proven inadequate in mitigating relapses and halting disease progression. Innovative drug targets for preventing multiple sclerosis are still required. The objective of this study is to discover novel therapeutic targets for MS by integrating single-cell transcriptomics and Mendelian randomization analysis.
METHODS: The study integrated MS genome-wide association study (GWAS) data, single-cell transcriptomics (scRNA-seq), expression quantitative trait loci (eQTL), and protein quantitative trait loci (pQTL) data for analysis and utilized two-sample Mendelian randomization study to comprehend the causal relationship between proteins and MS. Sequential analyses involving colocalization and Phenome-wide association studies (PheWAS) were conducted to validate the causal role of candidate genes.
RESULTS: Following stringent quality control preprocessing of scRNA-seq data, 1,123 expression changes across seven peripheral cell types were identified. Among the seven most prevalent cell types, 97 genes exhibiting at least one eQTL were discerned. Examination of MR associations between 28 proteins with available index pQTL signals and the risk of MS outcomes was conducted. Co-localization analyses and PheWAS indicated that FCRL3 may exert influence on MS.
CONCLUSION: The integration of scRNA-seq and MR analysis facilitated the identification of potential therapeutic targets for MS. Notably, FCRL3, implicated in immune function, emerged as a significant drug target in the deCODE databases. This research underscores the importance of FCRL3 in MS therapy and advocates for further investigation and clinical trials targeting FCRL3.
PURPOSE:To obtain the novel title compound soluble in oil for cosmetic, having excellent absorbing property in long wavelength area of ultraviolet ray, free from decomposition even under acidic conditions and useful as a ultraviolet absorber of cosmetic. CONSTITUTION:An organosilicon compound expressed by formula I [R<1> is formula II (R<3> is 1-30C alkyl, aryl, etc.; d is 0 or 1; n is 2-6); R<2> is H, hydroxy, etc.; a and bare 0 or 1 and a+b is 1 or 2; C is 0-5], e.g. a compound expressed by formula III. The compound expressed by formula I is obtained by condensing an alkenyloxy group-containing acetophenone compound expressed by formula IV and benzoic acid esters expressed by formula V under basic conditions to afford a compound expressed by formula VI and then subjecting the compound expressed by formula VI to addition reaction with an organohydrodienesilane expressed by the formula R<3>3SiH.
Subjects will receive an IV bolus injection of 18F-JNJ-64413739 for a PET/MR scan on Day 1 and a repeat 18F-JNJ-64413739 PET/magnetic resonance (MR) scan at least 1 week later to determine the test-retest variability in V\[t\]. 18F-JNJ-64413739 doses will be between 150 and 185 MBq.
Riluzole is a member of the benzothiazole class. The chemical designation for riluzole is 2-amino-6-(trifluoromethoxy)benzothiazole. Its molecular formula is C 8H 5F 3N 2OS, and its molecular weight is 234.2. The chemical structure is: 

Riluzole is a white to slightly yellow powder that is very soluble in dimethylformamide, dimethylsulfoxide, and methanol; freely soluble in dichloromethane; sparingly soluble in 0.1 N HCl; and very slightly soluble in water and in 0.1 N NaOH.

TIGLUTIK (50 mg/10mL) oral suspension is a slightly brown, opaque, homogeneous suspension containing 50 mg of riluzole per 10 mL of suspension.

TIGLUTIK also contains the following inactive ingredients: magnesium aluminum silicate, noncrystallizing sorbitol solution, polyoxyl 20 cetostearyl ether, purified water, saccharin sodium, simethicone emulsion, sodium lauryl sulfate, and xanthan gum.
The Xpert MTB/RIF test (Xpert) can help in the accurate screening of tuberculosis, however, its widespread use is limited by its high cost and lack of accessibility. Pooling of sputum samples for testing is a strategy to cut expenses and enhance population coverage but may result in a decrease in detection sensitivity due to the dilution of Mycobacterium tuberculosis (Mtb) by sample mixing. We investigated how the mixing ratio affected the detection performance of Xpert. We used frozen sputum samples that had been kept after individual Xpert assays of the sputa from Mtb-confirmed TB patients and non-TB patients. Our results showed that the overall sensitivity of the Xpert pooling assay remained higher than 80% when the mixing ratio was between 1/2 and 1/8. When the mixing ratio was raised to 1/16, the positive detection rate fell to 69.0%. For patients with either a high sputum Mtb smear score ≥ 2+, a time-to-positive culture ≤ 10 days, or an Xpert test indicating a high or medium abundance of bacteria, the pooling assay positivity rates were 93.3%, 96.8%, and 100% respectively, even at a 1/16 mixing ratio. For participants with cavities and cough, the pooling assay positivity rates were 86.2% and 90.0% at a 1/8 ratio, higher than for those without these signs. Our results show that the Xpert pooled assay has a high overall sensitivity, especially for highly infectious patients. This pooling strategy with lower reagent and labor costs could support TB screening in communities with limited resources, thereby facilitating reductions in the community transmission and incidence of TB worldwide.
BACKGROUND: Allergic rhinitis (AR) is an allergic disease characterized by the dominant differentiation of T helper cell 2 (Th2). BACH2 plays a key role in regulating Th2 immune response. This study aimed to explore the association between BACH2 single nucleotide polymorphism (SNPs) and susceptibility to AR.
METHODS: Han population from northern Shaanxi, China was chosen as subjects. After the DNA extraction from the peripheral blood of subjects, genotyping was completed through the Agena MassARRAY platform. Logistic regression analysis was used to assess the association. Multivariate dimensionality reduction (MDR) was used to evaluate the effect of the interaction between 'SNP-SNP' on susceptibility to AR. Using false-positive report probability (FPRP) analysis to test whether the significant results obtained in this study were noteworthy.
RESULTS: BACH2-rs905670 and -rs2134814 were significantly associated with increased risk of AR. The mutant allele 'A' of rs905670 (OR = 1.36, p = 0.018) and mutant allele 'G' of rs2134814 (OR = 1.34, p = 0.027) were risk genetic factors for AR. The above genetic association was further observed in the stratified analysis: BACH2-rs905670 and-rs2134814 were significantly associated with an increased risk of AR in females, aging older than 43 years, and participants working and living in the loess hills (OR > 1, p < 0.05).
CONCLUSION: BACH2-rs905670 and -rs2134814 are significantly associated with increasing AR risk.
The management of patients with acute angle-closure glaucoma requires therapeutic interventions in addition to ocular hypotensive agents. Dorzolamide HCl Ophthalmic Solution has not been studied in patients with acute angle-closure glaucoma.

Dorzolamide HCl Ophthalmic Solution has not been studied in patients with severe renal impairment (CrCl < 30 mL/min). Because Dorzolamide HCl Ophthalmic Solution and its metabolite are excreted predominantly by the kidney, Dorzolamide HCl Ophthalmic Solution is not recommended in such patients.

Dorzolamide HCl Ophthalmic Solution has not been studied in patients with hepatic impairment and should therefore be used with caution in such patients.

In clinical studies, local ocular adverse effects, primarily conjunctivitis and lid reactions, were reported with chronic administration of Dorzolamide HCl Ophthalmic Solution. Many of these reactions had the clinical appearance and course of an allergic-type reaction that resolved upon discontinuation of drug therapy. If such reactions are observed, Dorzolamide HCl Ophthalmic Solution should be discontinued and the patient evaluated before considering restarting the drug. (See ADVERSE REACTIONS)

There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and Dorzolamide HCl Ophthalmic Solution. The concomitant administration of Dorzolamide HCl Ophthalmic Solution and oral carbonic anhydrase inhibitors is not recommended.

There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface. Choroidal detachment has been reported with administration of aqueous suppressant therapy (e.g., dorzolamide) after filtration procedures.

There is an increased potential for developing corneal edema in patients with low endothelial cell counts. Precautions should be used when prescribing Dorzolamide HCl Ophthalmic Solution to this group of patients.
The invention relates to an antibody or antigen-binding fragment thereof which binds to the CXC chemokine receptor Bonzo (also referred to as STRL33, TYMSTR, HBMBU14 and CXCR6) and blocks the binding of a ligand (e.g., SExCkine (also referred to as chemokine alpha-5 and CXCL16) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to Bonzo and inhibit the binding of a ligand (e.g. SExCkine) and/or modulate a function of Bonzo. The invention relates to an antibody or antigen-binding fragment thereof which binds to the CXC chemokine SExCkine (also referred to as chemokine alpha-5) and inhibit binding of SExCkine to receptor (e.g., Bonzo). The invention also relates to targeting molecules which contain a first binding moiety which binds to mammalian Bonzo and a second binding moiety which binds to a molecule expressed on the surface of a target cell. The invention also relates to a method of promoting and/or effectuating the interaction of a Bonzo+ cell and a target cell. The invention further relates to a method of modulating a function of Bonzo, and to the use of the antibodies, antigen-binding fragments, targeting molecules and agents identified by the method of the invention in research, therapeutic, prophylactic and diagnostic methods.
PURPOSE:An agent for treating ulcers containing a lower alkyl or aralkyl alcoholic ester of salicylic acid as an active constituent. CONSTITUTION:A remedy for ulcers containing a lower alkyl or aralkyl alcoholic ester of salycilic acid, particularly benzyl salicylate, as an active constituent. An ester of the salicylic acid with an aliphatic lower alcohol, e.g. methyl alcohol, or aralkyl alcohol is cited as the alcoholic ester. The resultant remedy for ulcers is administered by the oral or parenteral route in various dosage forms of a tablet, capsule, etc., generally used as a medicine, and formulated with an excipient, preservative, etc. The dose thereof is selected from the range of 10-500mg, expressed in terms of the alcoholic ester of the salicylic acid which is the active constituent, a time and administered 1-3 times a day at need.
In the process an oil or fat which is solid at room temp. is dissolved by heating in an organic solvent which has little or no solvent power for the core material which is to be encapsulated but is capable of dissolving the oil or fat at elevated temp. and has coacervation properties for the oil or fat in the cold. The core material is dispersed in the solution obtd.; the dispersion is cooled with stirring to coacervate the oil or fat on the core material; and the resulting particulate product is separated off and dried. Method is used for microencapsulation of materials such as vitamins, minerals, amino acids, antibiotics, synthetic antibacterials, antiprotozoal agents, analgesics, antipyretics, enzymes, dried live microorganisms, foods, nutrients, and agricultural chemicals. The microencapsulation process makes use of the coacervation phenomenon without having to use a non-solvent in addition to the organic solvent.
FIELD: biotechnology, genetic engineering. SUBSTANCE: invention relates to recombinant polypeptide inhibiting adhesion and aggregation of platelets under pathological conditions (cerebrovascular and cardiovascular disorders). Recombinant polypeptide has binding region GPIb of human von Willebrand factor and definite amino acid sequence. Method of platelet aggregation inhibition is carried out by contact of platelets with effective amount of recombinant polypeptide. For expression of recombinant polypeptide the recombinant plasmid DNA pvWF-VC3 or pvWF-VCL is used. Each of DNA has a binding region of glycoprotein Ib of human von Willebrand factor. This region involves DNA-fragment encoding polypeptide amino acid sequence and has promoter system deo P 1 P 2  or promoter P λ  of lambda phage, deo-site of ribosome binding, T 1 T 2 -terminator of transcription and gene showing resistance to ampicillin Amp R  as a genetic marker. Producers of polypeptide - strain E. coli/pvWF-VC3 or /pvWF-VCL. For polypeptide preparing strain E. coli is transformed with recombinant plasmid DNA followed by selection and culturing transformants under conditions providing polypeptide accumulation. For isolation biologically active polypeptide bacterial cells are disrupted and lysate is obtained. From lysate inclusion bodies are isolated using denaturating agent or guanidine hydrochloride, or urea followed by purification of polypeptide solution by cation-exchange chromatography. Dissolved polypeptide is treated with disulfide or glutathione, or thioredoxin, or beta-mercaptoethanol, or cysteine. Prepared polypeptide is dialyzed and dialysate is subjected for cation-exchange chromatography. EFFECT: improved method of preparing. 7 cl, 4 tbl, 27 dwg
PCT No. PCT/US94/09648 Sec. 371 Date Mar. 28, 1996 Sec. 102(e) Date Mar. 28, 1996 PCT Filed Sep. 6, 1994 PCT Pub. No. WO95/11683 PCT Pub. Date May 4, 1995A stable and lyophilized formulation of prostaglandin E-1 made by the process comprising a) dissolving PGE-1 in a solution of lactose and tertiary butyl alcohol wherein said tertiary butyl alcohol is present in an amount of from about 15% to about 33% volume/volume and the ratio of said lactose to PGE-1 is from about 40,000 to 1 to about 10,000 to 1 weight/weight whereby a formulation of PGE-1dispersed in lactose is formed; b) adjusting and maintaining the pH of said formulation from about 3.5 to about 6 with an organic acid buffer; c) freezing said formulation to about -50 DEG  C.; and d) drying said formulation to obtain a moisture content of less than 1% by dry weight and a tertiary butyl alcohol content of less than 3% by dry weight. Preferably, step c) includes after freezing said formulation to about -50 DEG  C., warming to about -25 DEG  C. for about 2 hours then refreezing to about 50 DEG  C. Preferably, the prostaglandin is in an amount of about 25 to 100 ppm in lactose and the pH is maintained at about 4 to 5.
Provided herein are compositions comprising a CD112R antigen-binding protein, a TIGIT antigen-binding protein, and a PD-L1 antigen-binding protein. The composition in exemplary aspects comprises an anti-CD112R antibody, an anti-TIGIT antibody, and an anti-PD-L1 antibody, optionally, at about a 1:1:1 ratio. Also provided herein are methods of treating a subject comprising administering to the subject a CD112R antigen-binding protein, a TIGIT antigen-binding protein, and a PD-L1 antigen-binding protein, optionally, an anti-CD112R antibody, an anti-TIGIT antibody, and an anti-PD-L1 antibody. In exemplary instances, each antigen-binding protein is separately formulated and administered to the subject. In alternative aspects, at least two of the antibodies are formulated together and thus administered together. Optionally, at least the anti-CD112R and anti-TIGIT antibodies are co-formulated and co-administered and the anti-PD-L1 antibody is administered separately. In exemplary instances, the method comprises administering a composition comprising all three antigen-binding proteins.
The present invention provides neutralizing antitoxin directed against C.difficile toxins. These antitoxins are produced in avian species using soluble recombinant C.difficile toxin proteins. The avian antitoxins are designed so as to be orally administrable in therapeutic amounts and may be in any form (i.e., as a solid or in aqueous solution). Solid forms of the antitoxin may comprise an enteric coating. These antitoxins are useful in the treatment of humans and other animals intoxicated with at least one bacterial toxin. The invention further provides vaccines capable of protecting a vaccinated recipient from the morbidity and mortality associated with C.difficile infection. These vaccines are useful for administration to humans and other animals at risk of exposure to C.difficile toxins.